Predominant role of 25OHD in the negative regulation of PTH expression: Clinical relevance for hypovitaminosis D

Life Sciences

Volumn 82, Issue 13-14, 2008, Pages 677-683

  Kawahara, Masayuki ^a   Iwasaki, Yasumasa ^a   Sakaguchi, Kazushige ^b   Taguchi, Takafumi ^a   Nishiyama, Mitsuru ^a   Nigawara, Takeshi ^c   Tsugita, Makoto ^a   Kambayashi, Machiko ^a   Suda, Toshihoro ^c   Hashimoto, Kozo ^a  

^a KOCHI UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Hypovitaminosis D; Osteoporosis; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

HORMONE PRECURSOR; OXYGENASE; PARATHYROID HORMONE; VITAMIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOPOROSIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

ANIMALS; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; ENZYME INHIBITORS; FEEDBACK, BIOCHEMICAL; GENETIC VECTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KETOCONAZOLE; LUCIFERASES; MOLECULAR SEQUENCE DATA; PARATHYROID GLANDS; PARATHYROID HORMONE; PLASMIDS; PROMOTER REGIONS (GENETICS); RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROID HYDROXYLASES; TRANSCRIPTION, GENETIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 40649094686     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.12.027     Document Type: Article

References (34)

1. Alimov A.P., Langub M.C., Malluche H.H., Park-Sarge O.K., and Koszewski N.J. Contrasting mammalian parathyroid hormone (PTH) promoters: nuclear factor-Y binds to a deoxyribonucleic acid element unique to the human PTH promoter and acts as a transcriptional enhancer. Endocrinology 145 6 (2004) 2713-2720
2. Alimov A.P., Park-Sarge O.K., Sarge K.D., Malluche H.H., and Koszewski N.J. Transactivation of the parathyroid hormone promoter by specificity proteins and the nuclear factor Y complex. Endocrinology 146 8 (2005) 3409-3416
3. Aoki Y., Iwasaki Y., Katahira M., Oiso Y., and Saito H. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. I: effects of the common secretagogues. Endocrinology 138 5 (1997) 1923-1939
4. Barone A., Giusti A., Pioli G., Girasole G., Razzano M., Pizzonia M., Palummeri E., and Bianchi G. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Journal of American Geriatric Society 55 5 (2007) 752-757
5. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Hu F.B., Zhang Y., Karlson E.W., and Dawson-Hughes B. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. American Journal of Clinical Nutrition 80 3 (2004) 752-758
6. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., and Wong J.B. Effect of vitamin D on falls: a meta-analysis. JAMA 291 16 (2004) 1999-2006
7. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., and Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. American Journal of Medicine 116 9 (2004) 634-639
8. Bischoff-Ferrari H.A., Zhang Y., Kiel D.P., and Felson D.T. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. Arthritis & Rheumatism 53 6 (2005) 821-826
9. Christoffolete M.A., Ribeiro R., Singru P., Fekete C., da Silva W.S., Gordon D.F., Huang S.A., Crescenzi A., Harney J.W., Ridgway E.C., Larsen P.R., Lechan R.M., and Bianco A.C. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. Endocrinology 147 4 (2006) 1735-1743
10. Darwish H.M., and DeLuca H.F. Analysis of binding of the 1,25-dihydroxyvitamin D3 receptor to positive and negative vitamin D response elements. Archives of Biochemistry and Biophysics 334 2 (1996) 223-234
11. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. American Journal of Clinical Nutrition 80 6 Suppl. (2004) 1763S-1766S
12. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., and Vieth R. Estimates of optimal vitamin D status. Osteoporososis International 16 7 (2005) 713-716
13. He B., Tong T.K., Hiou-Tim F.F., Al-Akad B., Kronenberg H.M., and Karaplis A.C. The murine gene encoding parathyroid hormone: genomic organization, nucleotide sequence and transcriptional regulation. Journal of Molecular Endocrinology 29 2 (2002) 193-203
14. Holick M.F. Vitamin D deficiency. New England Journal of Medicine 357 3 (2007) 266-281
15. Jaaskelainen T., Huhtakangas J., and Maenpaa P.H. Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y. Biochemical and Biophysical Research Communications 328 4 (2005) 831-837
16. Jones G., Strugnell S.A., and DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiology Review 78 4 (1998) 1193-1231
17. Kato S., Fujiki R., and Kitagawa H. Vitamin D receptor (VDR) promoter targeting through a novel chromatin remodeling complex. Journal of Steroid Biochemistry and Molecular Biology 89-90 1-5 (2004) 173-178
18. Kato S., Kim M.S., Yamaoka K., and Fujiki R. Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D. Current Opinion in Nephrology and Hypertension 16 4 (2007) 297-304
19. Kim M.S., Fujiki R., Murayama A., Kitagawa H., Yamaoka K., Yamamoto Y., Mihara M., Takeyama K.I., and Kato S. 1α,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Molecular Endocrinology 21 2 (2007) 334-342
20. Koszewski N.J., Alimov A.P., Park-Sarge O.K., and Malluche H.H. Suppression of the human parathyroid hormone promoter by vitamin D involves displacement of NF-Y binding to the vitamin D response element. Journal of Biological Chemistry 279 41 (2004) 42431-42437
21. Larsen P.R., Dick T.E., Markovitz B.P., Kaplan M.M., and Gard T.G. Inhibition of intrapituitary thyroxine to 3.5.3′-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats. Journal of Clinical Investigation 64 1 (1979) 117-128
22. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Review 22 4 (2001) 477-501
23. Lips P., Duong T., Oleksik A., Black D., Cummings S., Cox D., and Nickelsen T. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. Journal of Clinical Endocrinology and Metabolism 86 3 (2001) 1212-1221
24. Liu S.M., Koszewski N., Lupez M., Malluche H.H., Olivera A., and Russell J. Characterization of a response element in the 5′-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Molecular Endocrinology 10 2 (1996) 206-215
25. Mackey S.L., Heymont J.L., Kronenberg H.M., and Demay M.B. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Molecular Endocrinology 10 3 (1996) 298-305
26. Matsushita A., Sasaki S., Kashiwabara Y., Nagayama K., Ohba K., Iwaki H., Misawa H., Ishizuka K., and Nakamura H. Essential role of GATA2 in the negative regulation of thyrotropin beta gene by thyroid hormone and its receptors. Molecular Endocrinology 21 4 (2007) 865-884
27. Odermatt A., Atanasov A.G., Balazs Z., Schweizer R.A., Nashev L.G., Schuster D., and Langer T. Why is 11β-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11β-HSD1. Molecular and Cellular Endocrinology 248 1-2 (2006) 15-23
28. Okazaki T., Igarashi T., and Kronenberg H.M. 5′-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. Journal of Biological Chemistry 263 5 (1988) 2203-2208
29. Parfitt A.M. Osteomalacia and related disorders. In: Avioli L.V., and Krane S.M. (Eds). Metabolic Bone Diseased and Clinically Related Disorders (1998), Academic Press, San Diego 327-386
30. Russell J., Ashok S., and Koszewski N.J. Vitamin D receptor interactions with the rat parathyroid hormone gene: synergistic effects between two negative vitamin D response elements. Journal of Bone and Mineral Research 14 11 (1999) 1828-1837
31. Sakaguchi K., Santora A., Zimering M., Curcio F., Aurbach G.D., and Brandi M.L. Functional epithelial cell line cloned from rat parathyroid glands. Proceedings of the National Academy of Science U.S.A. 84 10 (1987) 3269-3273
32. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. Journal of Bone Mineral Research 20 8 (2005) 1327-1333
33. Segersten U., Correa P., Hewison M., Hellman P., Dralle H., Carling T., Akerstrom G., and Westin G. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. Journal of Clinical Endocrinology and Metabolism 87 6 (2002) 2967-2972
34. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., Vamvakas E.C., Dick I.M., Prince R.L., and Finkelstein J.S. Hypovitaminosis D in medical inpatients. New England Journal of Medicine 338 12 (1998) 777-783